BRAF wild-type

News alerts, weekly reports and conference planners

Entrez ID:

673

Related biomarkers:

BRAF wild-type	Cutaneous Melanoma	BRAF wild-type	Cutaneous Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
BRAF wild-type	Cutaneous Melanoma	BRAF wild-type	Cutaneous Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF wild-type	Cutaneous Melanoma	BRAF wild-type	Cutaneous Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
BRAF wild-type	Colon Cancer	BRAF wild-type	Colon Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
BRAF wild-type	Colon Cancer	BRAF wild-type	Colon Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
BRAF wild-type	Rectal Cancer	BRAF wild-type	Rectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
BRAF wild-type	Rectal Cancer	BRAF wild-type	Rectal Cancer	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2	panitumumab Sensitive: A2 - Guideline panitumumab Sensitive : A2
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2	anlotinib Sensitive: C2 – Inclusion Criteria anlotinib Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2	CPGJ-602 Sensitive: C2 – Inclusion Criteria CPGJ-602 Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2	SCT200 Sensitive: C2 – Inclusion Criteria SCT200 Sensitive : C2
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	pembrolizumab + trametinib Sensitive: C3 – Early Trials pembrolizumab + trametinib Sensitive : C3	pembrolizumab + trametinib Sensitive: C3 – Early Trials pembrolizumab + trametinib Sensitive : C3
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
BRAF wild-type	Colorectal Cancer	BRAF wild-type	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
BRAF wild-type	Non Small Cell Lung Cancer	BRAF wild-type	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BRAF wild-type	Ovarian Cancer	BRAF wild-type	Ovarian Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRAF wild-type	Glioblastoma	BRAF wild-type	Glioblastoma	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3	panitumumab Sensitive: C3 – Early Trials panitumumab Sensitive : C3
BRAF wild-type	Melanoma	BRAF wild-type	Melanoma	dacarbazine Sensitive: C4 – Case Studies dacarbazine Sensitive : C4	dacarbazine Sensitive: C4 – Case Studies dacarbazine Sensitive : C4
BRAF wild-type	Cholangiocarcinoma	BRAF wild-type	Cholangiocarcinoma	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4

BRAF wild-type

Associations